This group comprises all hormonal preparations for systemic use, except:
- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.
|The DDDs are generally based on the treatment or diagnosis of endocrine disorders.|
H03 THYROID THERAPY
H03B ANTITHYROID PREPARATIONS
This group comprises preparations used in the treatment of hyperthyrosis.
|The DDDs are based on the treatment of hyperthyrosis.|
Last updated: 2015-12-16